Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUSTAIN-2: Long-term Safety of Intranasal Esketamine in TRD
NCT02497287Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2015
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 21
01
Overview
A Phase 3 trial of esketamine in treatment-resistant depression (TRD), sponsored by Janssen Pharmaceutical. Started Sep 2015; status: completed.
02
Drugs
esketamine
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT02497287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02497287.